Monte Rosa Therapeutics
GLUE
57 hedge funds and large institutions have $375M invested in Monte Rosa Therapeutics in 2022 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 19 increasing their positions, 15 reducing their positions, and 6 closing their positions.
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
27% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 15
10% more funds holding
Funds holding: 52 → 57 (+5)
2.79% less ownership
Funds ownership: 85.88% → 83.09% (-2.8%)
33% less capital invested
Capital invested by funds: $560M → $375M (-$185M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$3.29M |
| 2 |
BlackRock
New York
|
+$1.85M |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$1.02M |
| 4 |
State Street
Boston,
Massachusetts
|
+$817K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$730K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.86M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$7.43M |
| 3 |
CC
Casdin Capital
New York
|
-$4.52M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$1.14M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.02M |
GLUE Hedge Fund Activity: Q2 2022 in Review
57 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Monte Rosa Therapeutics (GLUE) for Q2 2022, worth a combined $375M — down 33% from $560M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new GLUE positions and 6 closed out — a net gain of 6 holders — while 19 added to existing stakes and 15 trimmed.
The largest buyer was Woodline Partners, adding an estimated $3.29M. The largest seller was Fidelity Investments, cutting an estimated $7.86M.
- 57 institutional investors held Monte Rosa Therapeutics (GLUE) as of Q2 2022, up from 52 in Q1 2022.
- Funds reported $375M of Monte Rosa Therapeutics stock for Q2 2022, down 33% quarter-over-quarter.
- 12 funds opened new Monte Rosa Therapeutics positions in Q2 2022 and 6 closed out, a net change of +6 holders.
- The largest Monte Rosa Therapeutics buyer in Q2 2022 was Woodline Partners, an estimated $3.29M added.
- The largest Monte Rosa Therapeutics seller in Q2 2022 was Fidelity Investments, an estimated $7.86M sold.
Based on aggregated 13F filings for Q2 2022.